You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 24, 2024

PROPRANOLOL HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Propranolol Hydrochloride, and what generic alternatives are available?

Propranolol Hydrochloride is a drug marketed by Actavis Elizabeth, Adare Pharms Inc, Amta, Extrovis, Inwood Labs, Lupin Ltd, Nortec Dev Assoc, Upsher Smith Labs, Zydus Pharms Usa Inc, Baxter Hlthcare Corp, Chartwell Injectable, Fosun Pharma, Fresenius Kabi Usa, Hikma Farmaceutica, Smith And Nephew, Solopak, Hikma, Pai Holdings Pharm, Aiping Pharm Inc, Ani Pharms, Chartwell Rx, Dava Pharms Inc, Duramed Pharms Barr, Endo Operations, Impax Labs Inc, Innogenix, Interpharm, Ipca Labs Ltd, Ivax Sub Teva Pharms, Lederle, Mylan, Northstar Hlthcare, Purepac Pharm, Roxane, Sandoz, Schering, Superpharm, Teva, Warner Chilcott, Watson Labs, Watson Labs Teva, and Rising. and is included in one hundred and thirty-eight NDAs.

The generic ingredient in PROPRANOLOL HYDROCHLORIDE is hydrochlorothiazide; propranolol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; propranolol hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PROPRANOLOL HYDROCHLORIDE?
  • What are the global sales for PROPRANOLOL HYDROCHLORIDE?
  • What is Average Wholesale Price for PROPRANOLOL HYDROCHLORIDE?
Drug patent expirations by year for PROPRANOLOL HYDROCHLORIDE
Recent Clinical Trials for PROPRANOLOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AIDS Malignancy ConsortiumPhase 2
Zealand University HospitalPhase 2
Rigshospitalet, DenmarkPhase 2

See all PROPRANOLOL HYDROCHLORIDE clinical trials

Pharmacology for PROPRANOLOL HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for PROPRANOLOL HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for PROPRANOLOL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for PROPRANOLOL HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
HEMANGEOL Oral Solution propranolol hydrochloride 4.28 mg/mL 205410 1 2022-07-21

US Patents and Regulatory Information for PROPRANOLOL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 070221-005 Sep 24, 1986 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lederle PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 072120-001 Jun 23, 1988 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma Farmaceutica PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride INJECTABLE;INJECTION 077760-001 Jan 31, 2008 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.